CSIMarket Company Name, Ticker, Competitors, else..
 
Axonics Inc   (NASDAQ: AXNX)
Other Ticker:  
 
 
Price: $70.9800 $0.53 0.752%
Day's High: $71.05 Week Perf: 0.8 %
Day's Low: $ 70.37 30 Day Perf: 1.05 %
Volume (M): 4,233 52 Wk High: $ 71.05
Volume (M$): $ 300,480 52 Wk Avg: $67.78
Open: $70.50 52 Wk Low: $55.09



 Market Capitalization (Millions $) 3,626
 Shares Outstanding (Millions) 51
 Employees 325
 Revenues (TTM) (Millions $) 431
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 114
 Capital Exp. (TTM) (Millions $) 9

Axonics Inc
Axonics Inc. is a medical technology company that develops and commercializes sacral neuromodulation systems for the treatment of urinary and bowel dysfunction. They are headquartered in Irvine, California, and operate globally.

Axonics' lead product, the Axonics Sacral Neuromodulation System, is a rechargeable implantable device that provides nerve stimulation to modulate the activity of the bladder and pelvic floor muscles. The device is implanted in the upper buttock area and connected to a lead that is positioned next to the sacral nerves. It is powered by a small, surgically-implanted battery that is designed to last up to 15 years. The device is controlled by a small, hand-held wireless programmer that allows patients to adjust the stimulation intensity and the frequency of the stimulation.

The Axonics system is designed to treat a range of clinical conditions, including overactive bladder, urinary retention, fecal incontinence, and chronic constipation. The system has been clinically proven to be safe and effective, with high success rates and low complication rates. Axonics received FDA approval in September 2019 for its sacral neuromodulation system for the treatment of patients with urinary dysfunction.

Axonics' mission is to provide patients suffering from urinary and bowel dysfunction with an alternative to traditional therapies such as medications and invasive surgeries. They focus on developing innovative technologies that are less invasive, more effective, and longer lasting than current treatments.

Axonics is committed to providing exceptional customer service and support to patients, healthcare providers, and their distribution partners. They have an experienced team of professionals dedicated to patient care and product development and are continuing to expand their global reach through regulatory approvals and partnerships.


   Company Address: 26 Technology Drive Irvine, 92618 CA
   Company Phone Number: 396-6322   Stock Exchange / Ticker: NASDAQ AXNX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BSX        0.03% 
INSP        0.61% 
MDT   -1.43%    
NVRO   -1.43%    
SYK   -1.71%    
TCMD   -1.68%    
• View Complete Report
   



Business Update

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia,

Published Thu, Sep 26 2024 12:47 PM UTC

Axonics Secures Regulatory Approval for Advanced Fourth-Generation Rechargeable SNM System in Australia Irvine, Calif. October 9, 2023 Axonics, Inc. (Nasdaq: AXNX), a global leader in the development of innovative therapies for the treatment of bladder and bowel dysfunction, has announced that it has obtained regulatory approval from the Therapeutic Goods Administratio...
Business Update

Axonics' Groundbreaking Recharge-Free SNM System Gains Regulatory Approval in Australia, Offering Relief for Overactive Bladder

Published Fri, May 17 2024 12:15 AM UTC

Axonics Receives Regulatory Approval for Game-Changing Sacral Neuromodulation System in AustraliaIn a groundbreaking move for the medical field, Axonics, Inc. has announced that its recharge-free sacral neuromodulation (SNM) system has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia. This approval marks a significant breakthrough in ...
Business Update

Axonics Unleashes Revolutionary Recharge-Free SNM System to Transform Overactive Bladder Treatment in Australia

Published Thu, May 16 2024 10:15 PM UTC

Axonics Revolutionizes Overactive Bladder Treatment with Recharge-Free SNM System Now Available in AustraliaIn a significant breakthrough for Australians plagued by bladder and bowel dysfunction, Axonics, Inc. (Nasdaq: AXNX) has proudly announced the regulatory approval granted by the Therapeutic Goods Administration (TGA) for marketing its groundbreaking Axonics F15 recharg...
Axonics Inc

Axonics Inc Surges in Revenue for Q1 2024, Despite Shortfall Concerns

Axonics Inc, a prominent Medical Equipment & Supplies company, recently announced a significant surge in revenue for the first quarter of 2024. The company's revenue increased by an impressive 29.162% to $91.25 million compared to the same period last year. While this growth is commendable, there is a cause for concern as they also revealed a shortfall per share amounting to $-0.38 per share.
Despite this shortfall, Axonics Inc's revenue improvement outperformed its competitors in the Medical Equipment & Supplies sector. This sector experienced an overall business rise of 9.75% during the same period, highlighting Axonics Inc's advantageous position.
Axonics Inc

2 Axonics Inc sets new standards in profitability and revenue growth in the Medical Equipment & Supplies sector



Axonics Inc, a prominent player in the Medical Equipment & Supplies sector, has recently reported remarkable financial results for the fiscal year ending on December 31, 2023. With soaring net profit per share and substantial revenue growth, the company has undoubtedly outperformed its sector peers. Moreover, Axonics Inc's improving profit margins, increasing inventories, and rising accounts receivable highlight a positive outlook for the company's future.
Skyrocketing Profitability and Revenue Growth:
In the fourth quarter of 2023, Axonics Inc witnessed an astounding 888.37% year-on-year increase in net profit per share, reaching $0.13 per share. This exceptional growth reflects the company's ability to optimize its operations and deliver superior financial performance. Additionally, revenue rose by an impressive 27.92% to reach $109.91 million in the same period. Axonics Inc's revenue growth is significantly higher than the 7.86% experienced by its sector peers, solidifying its position as a leader in the industry.






Axonics Inc's Segments
SNM net revenue    79.85 % of total Revenue
SNM net revenue United States    77.88 % of total Revenue
SNM net revenue International markets    1.97 % of total Revenue
Bulkamid net revenue    20.62 % of total Revenue
Bulkamid net revenue United States    16.47 % of total Revenue
Bulkamid net revenue International markets    4.15 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com